Objective:To observe the efficacy and safety of Etiasa,a control released tablet of mesalazine,in treatment of inflammatory
bowel disease(IBD) in comparison with
salicylazosulfapyridine (SASP).Methods:The randomized,multicenter,and controlled study was conducted in 89 patients with endoscopy confirmed mild or moderate ulcerative colitis (UC) or Crohn's disease (CD) of initial onset.They were randomly allocated to Etiasa ( n =52) or SASP( n =37)both in a dose of 1.0g qid for 6 weeks.After that they were examined by endoscopy.The efficacy and side effects were evaluated at week 4 and week 6.Results:There were 3 patients in SASP withdrawn from the study because of allergic reaction or leukopenia at the end of the 4th week.52 patients in Etiasa group and 34 patients in SASP group completed the study.The obvious improvement rate in Etiasa group at the end of the 4th and the 6th week is 52.0% and 71.2% respectively,by evaluation of patients vs 20.6% and 50.0% in SASP group ( P <0.05).Disappearance rate of GI symptoms at the end of the 6th week is 57.7% in Etiasa group vs 50.0% in SASP group( P <0.05).Cure rate confirmed by endoscopy at the end of the 6th week is 26.9% in Etiasa group vs 2.9% in SASP group ( P <0.05).The incidence of side effects is 1.9%(1/52) in Etiasa group vs 10.8%.(4/37) in SASP group( P >0.05)。Conclusion:Etiasa is an effective agent for treatment of IBD. <